Search results
Jul 20, 2021 · The U.S. Food and Drug Administration (FDA) recently issued a warning that the single-dose vaccine is associated with an increased risk of developing Guillain-Barré syndrome (GBS), a rare autoimmune disorder that attacks the body’s nerves. Here’s what you need to know, as explained by neurologist Kerry Levin, MD. 1.
Feb 15, 2023 · GBS is one of the serious neurologic adverse events, which may be the major source of vaccine hesitancy. However, the relationship between COVID-19 vaccination and GBS, actually described only in single case reports.
- Miao Yu, Shuang Nie, Yue Qiao, Ying Ma
- Front Immunol. 2023; 14: 1078197.
- 10.3389/fimmu.2023.1078197
- 2023
Dec 17, 2021 · We report the findings of two patients with Guillain-Barré syndrome after receiving the BNT162b2 vaccine (tozinameran, Pfizer–BioNTech) who were in complete remission from diffuse large B-cell lymphoma.
Guillain-Barré syndrome (GBS), an immune-mediated polyradiculoneuropathy with a ≈5% mortality rate, has an incidence worldwide of 0.81–1.91 cases/100,000 person-years (1). GBS has been reported to be associated with coronavirus disease (COVID-19) vaccination, but a comprehensive summary regarding this rare adverse event is still lacking.
We obtained data about self-reported patient demographic characteristics, clinical and medical history, COVID-19 vaccine type and vaccination date, history of flulike or gastrointestinal symptoms within 42 days of the most recent COVID-19 vaccination, and time to GBS symptom onset after vaccination.
Apr 26, 2022 · In this cohort study’s interim analyses conducted in a large population-based surveillance system that included medical record review of all potential GBS cases after COVID-19 vaccination through November 13, 2021, findings were consistent with an increased risk of GBS after Ad.26.COV2.S.
Jun 9, 2022 · Background and objective: The concern surrounding the association between Guillain-Barré syndrome (GBS) and vaccination has increased with the widespread use of COVID-19 vaccines. The aim of this study was to assess the potential association of GBS with mRNA-based or adenovirus-vectored COVID-19 vaccines.
